Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MDM2 positive |
| Therapy | Doxorubicin + YF438 |
| Indication/Tumor Type | triple-receptor negative breast cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MDM2 positive | triple-receptor negative breast cancer | sensitive | Doxorubicin + YF438 | Preclinical | Actionable | In a preclinical study, YF438 and Adriamycin (doxorubicin) combination treatment synergistically inhibited tumor growth compared to either drug alone in an orthotopic autograft model of triple-negative breast cancer (PMID: 33985974). | 33985974 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (33985974) | Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer. | Full reference... |